Uses Of Melanocortin 4 Receptor Agonist

Abstract: The present invention relates to uses of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing or treating rare genetic obesity diseases, particularly rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway.

Patent Information

Application #

Filing Date

17 August 2023

Publication Number

49/2023

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

LG CHEM, LTD.

128, Yeoui-daero Yeongdeungpo-gu Seoul 07336

Inventors

1. PARK, Hee Dong

E8 Block LG Science Park 30, Magokjungang 10-ro Gangseo-gu Seoul 07796

2. YEO, Su Jin

E8 Block LG Science Park 30, Magokjungang 10-ro Gangseo-gu Seoul 07796

3. AHN, Hye Won

E8 Block LG Science Park 30, Magokjungang 10-ro Gangseo-gu Seoul 07796

Specification

Documents

Application Documents

#	Name	Date
1	202317055240-STATEMENT OF UNDERTAKING (FORM 3) [17-08-2023(online)].pdf	2023-08-17
2	202317055240-REQUEST FOR EXAMINATION (FORM-18) [17-08-2023(online)].pdf	2023-08-17
3	202317055240-POWER OF AUTHORITY [17-08-2023(online)].pdf	2023-08-17
4	202317055240-FORM 18 [17-08-2023(online)].pdf	2023-08-17
5	202317055240-FORM 1 [17-08-2023(online)].pdf	2023-08-17
6	202317055240-DRAWINGS [17-08-2023(online)].pdf	2023-08-17
7	202317055240-DECLARATION OF INVENTORSHIP (FORM 5) [17-08-2023(online)].pdf	2023-08-17
8	202317055240-COMPLETE SPECIFICATION [17-08-2023(online)].pdf	2023-08-17
9	202317055240-Proof of Right [12-12-2023(online)].pdf	2023-12-12
10	202317055240-FORM 3 [12-12-2023(online)].pdf	2023-12-12
11	202317055240-FER.pdf	2025-06-09
12	202317055240-Information under section 8(2) [08-08-2025(online)].pdf	2025-08-08
13	202317055240-FORM 3 [08-08-2025(online)].pdf	2025-08-08

Search Strategy

1	202317055240_SearchStrategyNew_E_202317055240E_06-06-2025.pdf